POC Hematology Diagnostics Market Size
| Study Period | 2019 - 2030 |
| Market Size (2025) | USD 2.27 Billion |
| Market Size (2030) | USD 3.63 Billion |
| CAGR (2025 - 2030) | 9.80% |
| Fastest Growing Market | Asia Pacific |
| Largest Market | North America |
| Market Concentration | Medium |
Major Players*Disclaimer: Major Players sorted in no particular order |
POC Hematology Diagnostics Market Analysis
The Point-of-Care Hematology Diagnostics Market size is estimated at USD 2.27 billion in 2025, and is expected to reach USD 3.63 billion by 2030, at a CAGR of 9.8% during the forecast period (2025-2030).
The market for POC hematology diagnostics is expected to witness healthy growth during the forecast period. This growth is mainly due to the increasing incidences of blood disorders and rising usage of POC devices due to the benefits achieved.
Blood disorders, encompassing conditions such as anemia, hematological malignancies, hemorrhagic ailments, and blood infections, afflict millions of individuals annually, affecting individuals across all age ranges. According to a study published in ASH publications in May 2023, it is projected that by 2030, the total number of hematological malignancy cases will be as follows across different levels of Socio-Demographic Index (SDI): 1.1 million cases in high-SDI areas, 1.0 million cases in high-middle SDI areas, 0.47 million cases in low-SDI areas, 0.79 million cases in low-middle SDI areas, and 1.2 million cases in middle-SDI areas.
Additionally, the same source stated that the incidence rates per 100,000 individuals are expected to rise to 0.045 for multiple myeloma, 0.016 for leukemia, 0.012 for non-Hodgkin lymphoma, and 0.002 for Hodgkin lymphoma by 2030. Thus, an expected increase in hematological diseases will increase demand for POC hematology diagnostics, contributing to market growth.
The rising usage of point-of-care (POC) devices is attributed to numerous benefits, which include faster access to test results and expedited diagnosis and subsequent treatment. POC devices offer the advantage of reducing or eliminating operator and analytical errors, facilitating real-time access to results, and enabling timely care decisions by healthcare providers. These devices also contribute to improved patient outcomes, such as faster initiation of treatment for conditions like HIV and heart failure, resulting in shorter hospital stays and better healthcare and economic consequences.
Additionally, integrating POC devices into healthcare systems enhances patient care by providing immediate access to test results, supporting population health management, and enabling analytics-driven business decisions. The ease of use, robust storage of reagents, concordance with established laboratory methods, and safety features of POC devices make them essential tools in healthcare settings, especially for the timely detection of infectious diseases and improving healthcare delivery in resource-limited settings.
Moreover, market players are adopting several strategies, such as product launches, mergers, acquisitions, and collaboration, to stay competitive, which is expected to contribute to market growth during the forecast period. For instance, in May 2023, Siemens Healthineers unveiled the Atellica Hema 570 and Atellica Hema 580 Analyzers, two high-capacity hematology testing systems. The Atellica HEMA 570 and 580 Analyzers feature intuitive user interfaces and multi-analyzer automation integration, alleviating workflow bottlenecks and meeting the high-throughput needs of busy laboratories. Such launches of advanced POC hematology analyzers are expected to boost the market growth during the forecast period.
Hence, with the increasing burden of blood disorders, the market for POC hematology diagnostics is expected to grow.
POC Hematology Diagnostics Market Trends
Hematology Diagnostics Systems are Expected to Hold Major Share in the Market
A point-of-care (POC) hematology diagnostic system is a medical device or platform designed to perform hematology tests at or near the site of patient care, providing immediate results to healthcare professionals. These systems typically include instruments such as hematology analyzers, readers, and centrifuges to conduct tests, including complete blood counts, hemoglobin, hematocrit, and coagulation monitoring. With the rising blood disorders and increasing technological advancements in hematology analyzers, the systems segment of the market is expected to dominate.
The growing burden of blood diseases such as anemia and blood cancers like leukemia is expected to increase demand for hematology diagnostics systems, boosting segment growth. For instance, according to the Centers for Disease Control and Prevention data published in May 2023, sickle cell disease affects more than 100,000 newborns in the United States annually. The relatively high prevalence in the United States is due to the historical impact of the slave trade, as well as migration and settlement from regions where sickle cell disease is common. Thus, the high burden of sickle cell in the United States is expected to increase demand for effective POC hematology diagnostics segment, which is expected to drive the segment growth during the forecast period.
Also, increasing new product launches in the segment are propelling the growth. For instance, in August 2023, PixCell Medical announced FDA clearance for direct capillary sampling with the HemoScreen 5-part differential CBC analyzer. Direct capillary sampling with the HemoScreen analyzer simplifies blood sampling procedures and reduces pre-analytical steps. Such launches and approvals increase the advanced systems available in healthcare settings, contributing to the segment's growth.
Thus, the growing incidence of blood disorders and product approvals indicate the focus of diagnostics companies on coming up with POC hematology testing systems, fueling the segment growth.
North America is Expected to Hold a Significant Market Share During the Forecast Period
North America, one of the most developed healthcare industries, is expected to hold a significant share of the market for POC hematology diagnostics. The adoption of POC hematology testing is higher in the region, mainly attributed to the increased awareness of the benefits of point-of-care testing.
The high burden of hematology diseases is expected to contribute to the region's growth over the forecast period. According to the 2024 report from the American Cancer Society, there will be a total of 62,770 new cases of leukemia, 89,190 new cases of lymphoma, and 35,780 new cases of myeloma reported in the United States in 2024. These blood cancers were expected to account for 9.4% of the estimated 2.0 million new cancer cases in the country in 2023. Thus, growing blood cancer cases in the United States are expected to increase demand for POC hematology diagnostics during the forecast period.
Moreover, market players are adopting several strategies such as product launches, mergers, and acquisitions, and collaboration to stay competitive in the market is expected to contribute to market growth over the forecast period. For instance, in April 2024, PixCell Medical expanded its reach by forging strategic distribution partnerships with Medline, Henry Schein, and Thermo Fisher Scientific. Following recent partnerships with Henry Schein and Thermo Fisher Scientific, this latest agreement with Medline signifies a critical step in PixCell Medical's growth strategy. These partnerships are designed to increase accessibility to PixCell Medical's flagship product, the HemoScreen point-of-care Complete Blood Count (CBC) analyzer, across the United States. Such strategic activities by the market players in the region are expected to boost the region's market during the forecast period.
Thus, the region's high burden of blood cancer and strategic activities by the industry players are expected to boost the region's growth during the forecast period.
POC Hematology Diagnostics Industry Overview
The market for POC hematology diagnostics is semi-consolidated in terms of competition, and few companies are operating in this market. Market players are adopting several strategies, such as product launches, mergers and acquisitions, and collaboration, to stay competitive and expand their market share. Some major players are Abbott Laboratories, Sysmex Corporation, Danaher Corporation, Thermo Fisher Scientific, and F. Hoffmann-La Roche Ltd.
POC Hematology Diagnostics Market Leaders
-
Sysmex Corporation
-
Danaher Corporation (HemoCue AB)
-
Thermo Fisher Scientific
-
F. Hoffmann-La Roche Ltd
-
Abbott
- *Disclaimer: Major Players sorted in no particular order
POC Hematology Diagnostics Market News
- February 2024: Sysmex Corporation and CellaVision AB forged a strategic alliance to enhance hematology solutions. This collaboration will help Sysmex expand its portfolio with advanced cell morphology analyzers.
- January 2024: HORIBA Medical's new HELO 2.0 hematology platform, approved for use in the European Union under the new IVDR regulations, offered a high-throughput automated solution. Designed for scalability, HELO 2.0 is highly flexible and modular, enabling a range of configurations to suit the needs of laboratories of varying sizes, particularly those in the mid to large range.
POC Hematology Diagnostics Industry Segmentation
As per the scope of the report, point-of-care (POC) hematology diagnostics refer to diagnostic procedures conducted at or near the site of care, providing immediate results for hematological tests like complete blood counts, hemoglobin, hematocrit, and coagulation monitoring. These tests are crucial for rapid diagnosis, enabling timely interventions and tailored treatment plans. POC hematology diagnostics encompass a range of devices, such as hematology analyzers, readers, and centrifuges, offering quick and accurate results that aid in clinical decision-making and patient care.
The point-of-care (POC) hematology diagnostics market is segmented by product and geography. By product, the market is segmented into systems and consumables. The market is segmented by geography, such as North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (in USD) for the above segments.
| By Product | Systems | ||
| Consumables | |||
| Geography | North America | United States | |
| Canada | |||
| Mexico | |||
| Europe | Germany | ||
| United Kingdom | |||
| France | |||
| Italy | |||
| Spain | |||
| Rest of Europe | |||
| Asia-Pacific | China | ||
| Japan | |||
| India | |||
| Australia | |||
| South Korea | |||
| Rest of Asia-Pacific | |||
| Middle East and Africa | GCC | ||
| South Africa | |||
| Rest of Middle East and Africa | |||
| South America | Brazil | ||
| Argentina | |||
| Rest of South America | |||
| Systems |
| Consumables |
| North America | United States |
| Canada | |
| Mexico | |
| Europe | Germany |
| United Kingdom | |
| France | |
| Italy | |
| Spain | |
| Rest of Europe | |
| Asia-Pacific | China |
| Japan | |
| India | |
| Australia | |
| South Korea | |
| Rest of Asia-Pacific | |
| Middle East and Africa | GCC |
| South Africa | |
| Rest of Middle East and Africa | |
| South America | Brazil |
| Argentina | |
| Rest of South America |
Point-of-Care Hematology Diagnostics Market Research FAQs
How big is the Point-of-Care Hematology Diagnostics Market?
The Point-of-Care Hematology Diagnostics Market size is expected to reach USD 2.27 billion in 2025 and grow at a CAGR of 9.80% to reach USD 3.63 billion by 2030.
What is the current Point-of-Care Hematology Diagnostics Market size?
In 2025, the Point-of-Care Hematology Diagnostics Market size is expected to reach USD 2.27 billion.
Who are the key players in Point-of-Care Hematology Diagnostics Market?
Sysmex Corporation, Danaher Corporation (HemoCue AB), Thermo Fisher Scientific, F. Hoffmann-La Roche Ltd and Abbott are the major companies operating in the Point-of-Care Hematology Diagnostics Market.
Which is the fastest growing region in Point-of-Care Hematology Diagnostics Market?
Asia Pacific is estimated to grow at the highest CAGR over the forecast period (2025-2030).
Which region has the biggest share in Point-of-Care Hematology Diagnostics Market?
In 2025, the North America accounts for the largest market share in Point-of-Care Hematology Diagnostics Market.
What years does this Point-of-Care Hematology Diagnostics Market cover, and what was the market size in 2024?
In 2024, the Point-of-Care Hematology Diagnostics Market size was estimated at USD 2.05 billion. The report covers the Point-of-Care Hematology Diagnostics Market historical market size for years: 2019, 2020, 2021, 2022, 2023 and 2024. The report also forecasts the Point-of-Care Hematology Diagnostics Market size for years: 2025, 2026, 2027, 2028, 2029 and 2030.
Point-of-Care Hematology Diagnostics Industry Report
Statistics for the 2025 Point-of-Care Hematology Diagnostics market share, size and revenue growth rate, created by Mordor Intelligence™ Industry Reports. Point-of-Care Hematology Diagnostics analysis includes a market forecast outlook for 2025 to 2030 and historical overview. Get a sample of this industry analysis as a free report PDF download.
